Correction to Lancet Diabetes Endocrinol 2018; 6: 82 –83
Publication date: June 2018 Source:The Lancet Diabetes & Endocrinology, Volume 6, Issue 6 (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - May 24, 2018 Category: Endocrinology Source Type: research

Changing the conversation
Publication date: June 2018 Source:The Lancet Diabetes & Endocrinology, Volume 6, Issue 6 Author(s): Jules Morgan (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - May 24, 2018 Category: Endocrinology Source Type: research

Making the impossible possible
Publication date: June 2018 Source:The Lancet Diabetes & Endocrinology, Volume 6, Issue 6 Author(s): Robert Stirrups (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - May 24, 2018 Category: Endocrinology Source Type: research

Research digest: assessment and risks of obesity
Publication date: June 2018 Source:The Lancet Diabetes & Endocrinology, Volume 6, Issue 6 Author(s): Naveed Sattar, David Preiss (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - May 24, 2018 Category: Endocrinology Source Type: research

Novel diabetes subgroups – Authors' reply
Publication date: June 2018 Source:The Lancet Diabetes & Endocrinology, Volume 6, Issue 6 Author(s): Emma Ahlqvist, Rashmi B Prasad, Tiinamaija Tuomi, Anders Rosengren, Leif Groop (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - May 24, 2018 Category: Endocrinology Source Type: research

Novel diabetes subgroups
Publication date: June 2018 Source:The Lancet Diabetes & Endocrinology, Volume 6, Issue 6 Author(s): Deep Dutta, Satinath Mukhopadhyay (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - May 24, 2018 Category: Endocrinology Source Type: research

Retraction and republication —Worldwide burden of cancer attributable to diabetes and high body-mass index: a comparative risk assessment
Publication date: June 2018 Source:The Lancet Diabetes & Endocrinology, Volume 6, Issue 6 Author(s): The Editors of The Lancet Diabetes & Endocrinology (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - May 24, 2018 Category: Endocrinology Source Type: research

Transgender health: access to care under threat
Publication date: June 2018 Source:The Lancet Diabetes & Endocrinology, Volume 6, Issue 6 Author(s): The Lancet Diabetes & Endocrinology (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - May 24, 2018 Category: Endocrinology Source Type: research

Psoriasis: a novel risk factor for type 2 diabetes
Publication date: Available online 21 May 2018 Source:The Lancet Diabetes & Endocrinology Author(s): Joel M Gelfand, Marilyn T Wan (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - May 22, 2018 Category: Endocrinology Source Type: research

Islet transplantation versus insulin therapy in patients with type 1 diabetes with severe hypoglycaemia or poorly controlled glycaemia after kidney transplantation (TRIMECO): a multicentre, randomised controlled trial
Publication date: Available online 15 May 2018 Source:The Lancet Diabetes & Endocrinology Author(s): Sandrine Lablanche, Marie-Christine Vantyghem, Laurence Kessler, Anne Wojtusciszyn, Sophie Borot, Charles Thivolet, Sophie Girerd, Domenico Bosco, Jean-Luc Bosson, Cyrille Colin, Rachel Tetaz, Sophie Logerot, Julie Kerr-Conte, Eric Renard, Alfred Penfornis, Emmanuel Morelon, Fanny Buron, Kristina Skaare, Gwen Grguric, Coralie Camillo-Brault, Harald Egelhofer, Kanza Benomar, Lionel Badet, Thierry Berney, François Pattou, Pierre-Yves Benhamou Background Islet transplantation is indicated for patients with type...
Source: The Lancet Diabetes and Endocrinology - May 16, 2018 Category: Endocrinology Source Type: research

Islet transplantation in type 1 diabetes: moving forward
Publication date: Available online 15 May 2018 Source:The Lancet Diabetes & Endocrinology Author(s): Shareen Forbes, Peter A Senior, A M James Shapiro (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - May 16, 2018 Category: Endocrinology Source Type: research

Correction to Lancet Diabetes Endocrinol 2018; published online May 4. http://dx.doi.org/10.1016/S2213-8587(18)30105-0
Publication date: Available online 10 May 2018 Source:The Lancet Diabetes & Endocrinology (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - May 11, 2018 Category: Endocrinology Source Type: research

Sex-specific relevance of diabetes to occlusive vascular and other mortality: a collaborative meta-analysis of individual data from 980  793 adults from 68 prospective studies
Publication date: Available online 8 May 2018 Source:The Lancet Diabetes & Endocrinology Author(s): Prospective Studies Collaboration and Asia Pacific Cohort Studies CollaborationLGnatiucWGHerringtonJHalseyJTuomilehtoXFangHCKimDDe BacquerAJDobsonMHCriquiDRJacobsJrDALeonSAEPetersHUeshimaPSherlikerRPetoRCollinsRRHuxleyJREmbersonMWoodwardSLewingtonNAokiHArimaEArnesenAAromaaGAssmannDLBachmanCBaigentHBartholomewABenetosCBengtssonDBennettCBjörkelundHBlackburnKBonaaEBoyleRBroadhurstJCarstensenLChamblessZChenSKChewRClarkeCCoxJDCurbRD'AgostinoCDateGDavey SmithGDe BackerSSDhaliwalXFDuanPDucimetiereSDuffyHEliassenPElwoo...
Source: The Lancet Diabetes and Endocrinology - May 9, 2018 Category: Endocrinology Source Type: research

Diabetes and cardiovascular mortality: the impact of sex
Publication date: Available online 8 May 2018 Source:The Lancet Diabetes & Endocrinology Author(s): Anna Norhammar (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - May 9, 2018 Category: Endocrinology Source Type: research

New hope for glucokinase activators in type 2 diabetes?
Publication date: Available online 4 May 2018 Source:The Lancet Diabetes & Endocrinology Author(s): André J Scheen (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - May 5, 2018 Category: Endocrinology Source Type: research

Dorzagliatin monotherapy in Chinese patients with type 2 diabetes: a dose-ranging, randomised, double-blind, placebo-controlled, phase 2 study
This study is registered with ClinicalTrials.gov, number NCT02561338. Findings Between Sept 29, 2015, and Aug 17, 2016, we randomly assigned 258 patients to one of the five study groups. At the end of 12 weeks, the least squares mean change in HbA1c from baseline was −0·35% (95% CI −0·60 to −0·10) in the placebo group, −0·39% (−0·64 to −0·14) in the 75 mg once daily group, −0·65% (−0·92 to −0·38) in the 100 mg once daily group, −0·79% (−1·06 to −0·52) in the 50 mg twice...
Source: The Lancet Diabetes and Endocrinology - May 5, 2018 Category: Endocrinology Source Type: research

Precision medicine in the management of type 2 diabetes
Publication date: Available online 23 April 2018 Source:The Lancet Diabetes & Endocrinology Author(s): Anna L Gloyn, Daniel J Drucker The study of type 2 diabetes has been driven by advances in human genetics, epigenetics, biomarkers, mechanistic studies, and large clinical trials, enabling new insights into disease susceptibility, pathophysiology, progression, and development of complications. Simultaneously, several new drug classes with different mechanisms of action have been introduced over the past two decades, accompanied by data about cardiovascular safety and non-glycaemic outcomes. In this Review, we cri...
Source: The Lancet Diabetes and Endocrinology - April 24, 2018 Category: Endocrinology Source Type: research

Target blood pressure and kidney protection
Publication date: Available online 21 April 2018 Source:The Lancet Diabetes & Endocrinology Author(s): Giuseppe Mancia (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - April 22, 2018 Category: Endocrinology Source Type: research

Intensive systolic blood pressure control and incident chronic kidney disease in people with and without diabetes mellitus: secondary analyses of two randomised controlled trials
Publication date: Available online 21 April 2018 Source:The Lancet Diabetes & Endocrinology Author(s): Srinivasan Beddhu, Tom Greene, Robert Boucher, William C Cushman, Guo Wei, Gregory Stoddard, Joachim H Ix, Michel Chonchol, Holly Kramer, Alfred K Cheung, Paul L Kimmel, Paul K Whelton, Glenn M Chertow Background Guidelines, including the 2017 American College of Cardiology and American Heart Association blood pressure guideline, recommend tighter control of systolic blood pressure in people with type 2 diabetes. However, it is unclear whether intensive lowering of systolic blood pressure increases the incidence ...
Source: The Lancet Diabetes and Endocrinology - April 22, 2018 Category: Endocrinology Source Type: research

Mean HbA1c, HbA1c variability, and mortality in people with diabetes aged 70 years and older: a retrospective cohort study
Publication date: Available online 16 April 2018 Source:The Lancet Diabetes & Endocrinology Author(s): Angus Forbes, Trevor Murrells, Henrietta Mulnier, Alan J Sinclair Background Glycaemic targets for older people have been revised in recent years because of concern that more stringent targets are associated with increased mortality. We aimed to investigate the association between glycaemic control (mean HbA1c) and variability (variability of HbA1c over time) and mortality in older people with diabetes. Methods We did a 5-year retrospective cohort study using The Health Improvement Network database, which include...
Source: The Lancet Diabetes and Endocrinology - April 19, 2018 Category: Endocrinology Source Type: research

Glycaemic control and glycaemic variability in older people with diabetes
Publication date: Available online 16 April 2018 Source:The Lancet Diabetes & Endocrinology Author(s): Hermes J Florez (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - April 19, 2018 Category: Endocrinology Source Type: research

Peer guidance for young people with type 1 diabetes
Publication date: May 2018 Source:The Lancet Diabetes & Endocrinology, Volume 6, Issue 5 Author(s): Miriam E Tucker (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - April 19, 2018 Category: Endocrinology Source Type: research

Diabetes behind bars: challenging inadequate care in prisons
Publication date: May 2018 Source:The Lancet Diabetes & Endocrinology, Volume 6, Issue 5 Author(s): The Lancet Diabetes & Endocrinology (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - April 19, 2018 Category: Endocrinology Source Type: research

Correction to Lancet Diabetes Endocrinol 2018; 6: 274
Publication date: Available online 13 April 2018 Source:The Lancet Diabetes & Endocrinology (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - April 14, 2018 Category: Endocrinology Source Type: research

Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin-angiotensin system: a secondary analysis of the PARADIGM-HF trial
Publication date: Available online 13 April 2018 Source:The Lancet Diabetes & Endocrinology Author(s): Milton Packer, Brian Claggett, Martin P Lefkowitz, John J V McMurray, Jean L Rouleau, Scott D Solomon, Michael R Zile Background Neprilysin inhibition has favourable effects on experimental diabetic nephropathy. We sought to assess the effects of neprilysin inhibition on the course of renal function in patients with type 2 diabetes. Methods In the randomised, double-blind PARADIGM-HF trial, the effects of sacubitril/valsartan (97 mg/103 mg twice daily) were compared with enalapril (10 mg twice daily) in 8399 pati...
Source: The Lancet Diabetes and Endocrinology - April 14, 2018 Category: Endocrinology Source Type: research

Correction to Lancet Diabetes Endocrinol 2017; 5: 680 –81
Publication date: Available online 13 April 2018 Source:The Lancet Diabetes & Endocrinology (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - April 14, 2018 Category: Endocrinology Source Type: research

Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies
Publication date: Available online 11 April 2018 Source:The Lancet Diabetes & Endocrinology Author(s): Bryan Williams, Thomas M MacDonald, Steve V Morant, David J Webb, Peter Sever, Gordon T McInnes, Ian Ford, J Kennedy Cruickshank, Mark J Caulfield, Sandosh Padmanabhan, Isla S Mackenzie, Jackie Salsbury, Morris J Brown Background In the PATHWAY-2 study of resistant hypertension, spironolactone reduced blood pressure substantially more than conventional antihypertensive drugs. We did three substudies to assess the mechanisms underlying this superiority and the pathogenesis of resistant hypertension. Methods PATHWA...
Source: The Lancet Diabetes and Endocrinology - April 12, 2018 Category: Endocrinology Source Type: research

Fluid retention, aldosterone excess, and treatment of resistant hypertension
Publication date: Available online 11 April 2018 Source:The Lancet Diabetes & Endocrinology Author(s): David A Calhoun (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - April 12, 2018 Category: Endocrinology Source Type: research

Correction to Lancet Diabetes Endocrinol 2018; published online on Feb 20. http://dx.doi.org/10.1016/S2213-8587(18)30035-4
Publication date: Available online 10 April 2018 Source:The Lancet Diabetes & Endocrinology (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - April 11, 2018 Category: Endocrinology Source Type: research

Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study
This study is registered with ClinicalTrials.gov (NCT01575873) and is completed. Findings Between March 28, 2012, and June 30, 2015, 795 patients, 505 of whom were glucocorticoid continuing and 290 of whom were glucocorticoid initiating, were enrolled and randomly assigned (398 to denosumab, 397 to risedronate). Denosumab was both non-inferior and superior to risedronate at 12 months for effect on bone mineral density at the lumbar spine in both glucocorticoid-continuing (4·4% [95% CI 3·8–5·0] vs 2·3% [1·7–2·9]; p<0·0001) and glucocorticoid-initiating (3&m...
Source: The Lancet Diabetes and Endocrinology - April 7, 2018 Category: Endocrinology Source Type: research

Denosumab: a new treatment option for glucocorticoid-induced osteoporosis
Publication date: Available online 6 April 2018 Source:The Lancet Diabetes & Endocrinology Author(s): Elena Tsourdi, Lorenz C Hofbauer (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - April 7, 2018 Category: Endocrinology Source Type: research

Bone health during endocrine therapy for cancer
Publication date: Available online 20 March 2018 Source:The Lancet Diabetes & Endocrinology Author(s): Tilman D Rachner, Robert Coleman, Peyman Hadji, Lorenz C Hofbauer Preservation of bone health remains a long-term clinical challenge in patients with breast and prostate cancer. Osteoporosis, defined by a loss of bone mass and microarchitecture, often results in fragility fractures that are typically associated with a high socioeconomic burden. Endocrine therapy, a mainstay treatment in the management of patients with hormone-sensitive breast and prostate cancer in the adjuvant setting, commonly exerts adverse ef...
Source: The Lancet Diabetes and Endocrinology - March 21, 2018 Category: Endocrinology Source Type: research

Juleen Zierath: in pursuit of curiosity
Publication date: April 2018 Source:The Lancet Diabetes & Endocrinology, Volume 6, Issue 4 Author(s): Fiona Mitchell (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - March 21, 2018 Category: Endocrinology Source Type: research

Eating disorders and type 1 diabetes: a challenging combination
Publication date: April 2018 Source:The Lancet Diabetes & Endocrinology, Volume 6, Issue 4 Author(s): Janet Treasure (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - March 21, 2018 Category: Endocrinology Source Type: research

Research digest: updates on diabetes in pregnancy
Publication date: April 2018 Source:The Lancet Diabetes & Endocrinology, Volume 6, Issue 4 Author(s): Naveed Sattar, David Preiss (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - March 21, 2018 Category: Endocrinology Source Type: research

Once-daily, modified-release hydrocortisone in patients with adrenal insufficiency – Authors' reply
Publication date: April 2018 Source:The Lancet Diabetes & Endocrinology, Volume 6, Issue 4 Author(s): Andrea M Isidori, Valeria Hasenmajer, Mary Anna Venneri (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - March 21, 2018 Category: Endocrinology Source Type: research

Once-daily, modified-release hydrocortisone in patients with adrenal insufficiency
Publication date: April 2018 Source:The Lancet Diabetes & Endocrinology, Volume 6, Issue 4 Author(s): Bernard Khoo (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - March 21, 2018 Category: Endocrinology Source Type: research

Gout: a patrician malady no more
Publication date: April 2018 Source:The Lancet Diabetes & Endocrinology, Volume 6, Issue 4 Author(s): Puja P Khanna (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - March 21, 2018 Category: Endocrinology Source Type: research

Screening thresholds: one size does not fit all
Publication date: April 2018 Source:The Lancet Diabetes & Endocrinology, Volume 6, Issue 4 Author(s): The Lancet Diabetes & Endocrinology (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - March 21, 2018 Category: Endocrinology Source Type: research

Diabetes duration, HbA1c, and cause-specific mortality in Mexico
Publication date: Available online 19 March 2018 Source:The Lancet Diabetes & Endocrinology Author(s): Armando Arredondo (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - March 20, 2018 Category: Endocrinology Source Type: research

Effect of diabetes duration and glycaemic control on 14-year cause-specific mortality in Mexican adults: a blood-based prospective cohort study
Publication date: Available online 19 March 2018 Source:The Lancet Diabetes & Endocrinology Author(s): William G Herrington, Jesus Alegre-Díaz, Rachel Wade, Louisa Gnatiuc, Raúl Ramirez-Reyes, Michael Hill, Martha Solano-Sánchez, Colin Baigent, Sarah Lewington, Rory Collins, Roberto Tapia-Conyer, Richard Peto, Pablo Kuri-Morales, Jonathan R Emberson Background Diabetes is a cause of at least a third of all deaths in Mexican adults aged 35–74 years, with the excess mortality due mainly to vascular disease, renal disease, infection, and acute diabetic crises. We aimed to analyse the effect...
Source: The Lancet Diabetes and Endocrinology - March 20, 2018 Category: Endocrinology Source Type: research

Correction to Lancet Diabetes Endocrinol 2018; 6: 186 –96
Publication date: Available online 6 March 2018 Source:The Lancet Diabetes & Endocrinology (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - March 8, 2018 Category: Endocrinology Source Type: research

Clinical efficacy and safety of a light mask for prevention of dark adaptation in treating and preventing progression of early diabetic macular oedema at 24 months (CLEOPATRA): a multicentre, phase 3, randomised controlled trial
Publication date: Available online 5 March 2018 Source:The Lancet Diabetes & Endocrinology Author(s): Sobha Sivaprasad, Joana C Vasconcelos, A Toby Prevost, Helen Holmes, Philip Hykin, Sheena George, Caroline Murphy, Joanna Kelly, Geoffrey B Arden Background We aimed to assess 24-month outcomes of wearing an organic light-emitting sleep mask as an intervention to treat and prevent progression of non-central diabetic macular oedema. Methods CLEOPATRA was a phase 3, single-blind, parallel-group, randomised controlled trial undertaken at 15 ophthalmic centres in the UK. Adults with non-centre-involving diabetic macul...
Source: The Lancet Diabetes and Endocrinology - March 6, 2018 Category: Endocrinology Source Type: research

Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables
Publication date: Available online 5 March 2018 Source:The Lancet Diabetes & Endocrinology Author(s): Emma Ahlqvist, Petter Storm, Annemari Käräjämäki, Mats Martinell, Mozhgan Dorkhan, Annelie Carlsson, Petter Vikman, Rashmi B Prasad, Dina Mansour Aly, Peter Almgren, Ylva Wessman, Nael Shaat, Peter Spégel, Hindrik Mulder, Eero Lindholm, Olle Melander, Ola Hansson, Ulf Malmqvist, Åke Lernmark, Kaj Lahti, Tom Forsén, Tiinamaija Tuomi, Anders H Rosengren, Leif Groop Background Diabetes is presently classified into two main forms, type 1 and type 2 diabetes, but type 2 diabetes ...
Source: The Lancet Diabetes and Endocrinology - March 6, 2018 Category: Endocrinology Source Type: research

Are light masks useful for early diabetic macular oedema?
Publication date: Available online 5 March 2018 Source:The Lancet Diabetes & Endocrinology Author(s): Tien Yin Wong (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - March 6, 2018 Category: Endocrinology Source Type: research

The many faces of diabetes: addressing heterogeneity of a complex disease
Publication date: Available online 1 March 2018 Source:The Lancet Diabetes & Endocrinology Author(s): Rob Sladek (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - March 2, 2018 Category: Endocrinology Source Type: research

Do sulphonylureas still have a place in clinical practice?
Publication date: Available online 28 February 2018 Source:The Lancet Diabetes & Endocrinology Author(s): Kamlesh Khunti, Sudesna Chatterjee, Hertzel C Gerstein, Sophia Zoungas, Melanie J Davies Sulphonylureas have been commercially available since the 1950s, but their use continues to be associated with controversy. Although adverse cardiovascular outcomes in some observational studies have raised concerns about sulphonylureas, findings from relatively recent, robust, and high-quality systematic reviews have indicated no increased risk of all-cause mortality associated with sulphonylureas compared with other acti...
Source: The Lancet Diabetes and Endocrinology - March 1, 2018 Category: Endocrinology Source Type: research

Does addressing prediabetes help to improve population health?
Publication date: Available online 27 February 2018 Source:The Lancet Diabetes & Endocrinology Author(s): Mika Kivimäki, Adam G Tabák (Source: The Lancet Diabetes and Endocrinology)
Source: The Lancet Diabetes and Endocrinology - February 28, 2018 Category: Endocrinology Source Type: research

Cardiovascular and renal burdens of prediabetes in the USA: analysis of data from serial cross-sectional surveys, 1988 –2014
Publication date: Available online 27 February 2018 Source:The Lancet Diabetes & Endocrinology Author(s): Mohammed K Ali, Kai McKeever Bullard, Sharon Saydah, Giuseppina Imperatore, Edward W Gregg Background There is controversy over the usefulness of prediabetes as a diagnostic label. Using data from US National Health and Nutrition Examination Surveys (NHANES) between 1988 and 2014, we examined the cardiovascular and renal burdens in adults with prediabetes over time and compared patterns with other glycaemic status groups. Methods We analysed cross-sectional survey data from non-pregnant adults aged 20 years an...
Source: The Lancet Diabetes and Endocrinology - February 28, 2018 Category: Endocrinology Source Type: research

Effect of fenofibrate on uric acid and gout in type 2 diabetes: a post-hoc analysis of the randomised, controlled FIELD study
Publication date: Available online 26 February 2018 Source:The Lancet Diabetes & Endocrinology Author(s): Boris Waldman, Jean-Claude Ansquer, David R Sullivan, Alicia J Jenkins, Neil McGill, Luke Buizen, Timothy M E Davis, James D Best, Liping Li, Michael D Feher, Christelle Foucher, Y Antero Kesaniemi, Jeffrey Flack, Michael C d'Emden, Russell S Scott, John Hedley, Val Gebski, Anthony C Keech Background Gout is a painful disorder and is common in type 2 diabetes. Fenofibrate lowers uric acid and reduces gout attacks in small, short-term studies. Whether fenofibrate produces sustained reductions in uric acid and g...
Source: The Lancet Diabetes and Endocrinology - February 27, 2018 Category: Endocrinology Source Type: research